GLP-1 receptor agonists have emerged as a preferred first-line therapy because they can address cardiometabolic disease across multiple organ systems
Insufficient leptin signaling in the hypothalamus, which is caused by either decreased availability of leptin for transport to the hypothalamus (in the case of leptinopenia), or restricted leptin entry across the BBB (imposed by hyperleptinemia in obese subjects), is primarily responsible for inducing hyperglycemia and hyperinsulinemia
USA 110 , 14461451 (2013)
To date, Proba GLP-1 Stoffwechsel PRO has not been studied in women who are either pregnant, planning to become pregnant, or breastfeeding
Inclusion criteria required all participants to have no major recent or ongoing clinically significant pathology, active or chronic disease, or clinically significant findings upon physical examination, vital sign collection, 12-lead electrocardiogram (ECG), or laboratory assessments
Zepbound (tirzepatide) Zepbound is a once-weekly GIP/GLP-1 medication approved for chronic weight management in qualifying adults and for certain adults with obesity and moderate-to-severe obstructive sleep apnea